Mirae Asset Global Investments
ZYNE

Mirae Asset Global Investments’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Mirae Asset Global Investments’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-901,835
Closed -$660K – 2632
2022
Q3 		$660K Sell
901,835
-330,621
-27% -$375K ﹤0.01% 1718
2022
Q2 		$1.41M Sell
1,232,456
-12,785
-1% -$16.3K ﹤0.01% 1252
2022
Q1 		$2.55M Sell
1,245,241
-123,198
-9% -$293K 0.01% 1086
2021
Q4 		$3.94M Buy
1,368,439
+14,510
+1% +$53.7K 0.01% 947
2021
Q3 		$5.74M Sell
1,353,929
-284,471
-17% -$1.27M 0.01% 810
2021
Q2 		$8.67M Buy
1,638,400
+1,344,559
+458% +$6.46M 0.02% 692
2021
Q1 		$1.37M Sell
293,841
-356,040
-55% -$1.61M ﹤0.01% 1043
2020
Q4 		$2.15M Buy
649,881
+242,623
+60% +$921K 0.01% 900
2020
Q3 		$1.35M Buy
407,258
+54,466
+15% +$200K 0.01% 878
2020
Q2 		$1.19M Buy
352,792
+38,965
+12% +$184K 0.01% 848
2020
Q1 		$1.2M Buy
313,827
+11,032
+4% +$51.2K 0.01% 782
2019
Q4 		$1.83M Sell
302,795
-241,613
-44% -$1.65M 0.01% 769
2019
Q3 		$4.12M Buy
544,408
+139,848
+35% +$1.58M 0.03% 512
2019
Q2 		$5.48M Buy
+404,560
New +$4.67M 0.04% 435
2018
Q1 		– Sell
-361,062
Closed -$4.52M – 778
2017
Q4 		$4.52M Buy
361,062
+22,510
+7% +$258K 0.06% 195
2017
Q3 		$2.83M Buy
338,552
+35,442
+12% +$375K 0.05% 274
2017
Q2 		$5.14M Buy
+303,110
New +$6.03M 0.09% 149

Other funds holding ZYNE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $13B AUM 71.84% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
IEFM
IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return

Mirae Asset Global Investments's ZYNE Position: Q4 2022 in Review

Mirae Asset Global Investments sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q4 2022, closing a stake of 901,835 shares — an estimated $660K sold.

Mirae Asset Global Investments first reported a position in ZYNE in Q2 2017 and held it in 17 quarters. The position peaked at $8.67M in Q2 2021. 50 funds tracked by Wall St. Rank hold ZYNE as of Q4 2022.

  • Mirae Asset Global Investments reported no remaining Zynerba Pharmaceuticals, Inc position as of Q4 2022 after selling out during the quarter.
  • Mirae Asset Global Investments sold 901,835 Zynerba Pharmaceuticals, Inc shares in Q4 2022, an estimated $660K.
  • Mirae Asset Global Investments first reported a position in Zynerba Pharmaceuticals, Inc in Q2 2017 and held it in 17 quarters.
  • Mirae Asset Global Investments's Zynerba Pharmaceuticals, Inc position peaked at $8.67M in Q2 2021.
  • 50 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q4 2022.

Based on Mirae Asset Global Investments's 13F filing for Q4 2022, filed 9 Feb 2023.